Living Cell Technologies, Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Living Cell Technologies, Ltd.
With just enough cash to stay afloat until the first quarter, Midatech is linking up with US-based, Canada-listed Bioasis to create a new rare disease player, Biodexa.
VC Investment in South Korea’s biopharma sector drops again as investors continue to shy away amid higher interest rates and reduced out-licensing deals.
Special purpose acquisition companies can bring biopharma firms to market faster than a traditional initial public offering, but frequent failures and increased scrutiny from the US Securities and Exchange Commission mean their heyday in the life sciences space is arguably over.
Coronavirus Notebook: Veru’s Sabizabulin Prioritized By European & US Regulators, Kinarus’s KIN001 Offers ‘Synergistic Efficacy’
Sabizabulin is the first product to be assessed under the European Medicines Agency’s expanded mandate, and has also been filed for a US emergency use authorization. At global level, the World Health Organization has issued new guidance on the use of second booster doses of COVID-19 vaccines.
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.